Every 10-Q that Catalyst Pharmaceutical Inc. (CPRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CPRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CPRX filings page.
Catalyst Pharmaceuticals reported solid first-quarter 2026 results with continued profitability and strong cash generation. Total revenues were $149.4 million, up from $141.4 million a year earlier, driven by higher FIRDAPSE and AGAMREE sales, partly offset by lower FYCOMPA revenue.
Net income rose to $63.7 million, with diluted earnings per share of $0.50. Operating income reached $73.2 million, supported by disciplined R&D and stable SG&A spending. Cash from operating activities was $59.6 million, lifting cash and cash equivalents to $755.9 million and total assets to $1.15 billion as of March 31, 2026, with minimal debt-like obligations.
The business remains highly concentrated in three rare-disease and neurology products—FIRDAPSE, AGAMREE and FYCOMPA—with one major U.S. distributor accounting for about 90% of product revenue. The company also highlights strong patent and licensing positions, including settlements that delay FIRDAPSE generics into the 2030s. After quarter-end, Catalyst signed a definitive merger agreement to be acquired by Angelini Pharma, which would turn Catalyst into a wholly owned subsidiary, marking a major strategic shift for shareholders.
Catalyst Pharmaceuticals (CPRX) reported stronger Q3 2025 results. Total revenue reached $148.4 million, up from $128.7 million a year ago, driven by FIRDAPSE ($92.2 million), AGAMREE ($32.4 million), and FYCOMPA ($23.8 million). Operating income was $66.3 million and net income was $52.8 million, with diluted EPS of $0.42 versus $0.35 last year.
For the nine months, revenue rose to $436.4 million from $349.9 million, and net income increased to $161.6 million from $108.0 million. Cash and cash equivalents were $689.9 million, supported by $163.8 million in operating cash flow year-to-date. The balance sheet shows total assets of $1.05 billion, liabilities of $131.4 million, and stockholders’ equity of $920.2 million. Shares outstanding were 122,912,387 as of November 3, 2025.
Period: Quarterly report for Catalyst Pharmaceuticals, Inc. (CPRX) for the six months ended June 30, 2025.
Key financials: Total revenues $287,984 thousand; product revenue $287,940 thousand; operating income $129,665 thousand; net income $108,845 thousand; diluted EPS $0.86; cash and cash equivalents $652,800 thousand; total assets $971,915 thousand as of June 30, 2025.
Product mix and material items: FIRDAPSE $168,576 thousand, FYCOMPA $69,959 thousand, AGAMREE $49,405 thousand for the six months ended June 30, 2025. Customer A accounted for 75.3% of net product revenue for the six months ended June 30, 2025. Company states it has sufficient funds for at least 12 months and completed a public offering on January 9, 2024 raising net proceeds of approximately $140.7 million.